INTERCEPT® Blood System USA

The CDC has issued a Level 1 Travel Health Notice for Oropouche fever in the Americas after outbreaks in parts of Brazil, Bolivia, Columbia, Peru, and Cuba(1). Two travel-related cases of Oropouche fever have also been reported in the US.(2) Oropouche is spread by the bite of infected midges and mosquitos, with symptoms similar to dengue, including fever and nausea. Possible cases of pregnant mother-to-child transmission of Oropouche with adverse pregnancy outcomes are under investigation.(1) AABB is currently conducting surveillance on this virus to understand its potential threat to transfusion safety.(3) 1.Oropouche Fever in the Americas. CDC. https://ow.ly/UZwA50SStIC 2.Mosquito-Borne Disease Surveillance. Florida Department of Health. https://ow.ly/OxJR50SStf8 3.Emerging Infectious Disease Agents and their Potential Threat to Transfusion Safety. AABB. https://ow.ly/vHlO50SStfc ©2024 Cerus Corporation. MKT-EN 00685-57 v1.0

Join Cerus at the Society for the Advancement of Patient Blood Management, Inc. (SABM) 2024 Annual Meeting at the Hyatt Regency Phoenix in Phoenix, AZ, September 12–14, 2024! Be sure to attend Cerus’ Industry Workshop, “Protecting the Blood Supply with Pathogen Reduction: Current and Future Perspectives”, on September 12 at 3:00 p.m. The workshop features Nina Mufti, PhD discussing recent findings on the ReCePI trial, a Phase III trial evaluating the use of pathogen reduced red cell components in cardiovascular surgery patients¹ and Andrea McGonigle M.D. presenting on UCLA’s experience with Pathogen Reduced Cryoprecipitated Fibrinogen Complex, commonly referred to as INTERCEPT® Fibrinogen Complex (IFC), in postpartum hemorrhage. Register here: https://ow.ly/ksJ150SV6BN Please visit us at Booth #17 in the Exhibition Hall to learn more! Find out why hospitals are using INTERCEPT treated blood components: https://ow.ly/y2Pq50SV6BM #INTERCEPT #pathogeninactivation #JOINTHEMOVEMENT #IFC #bloodsafety #patientbloodmanagement 1. The INTERCEPT Red Blood Cell system is in clinical development. (ClinicalTrials.gov ID NCT03459287). INTERCEPT Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex: INDICATIONS FOR USE •Treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. • Control of bleeding when recombinant and/or specific virally inactivated preparations of factor XIII or von Willebrand factor (vWF) are not available. • Second-line therapy for von Willebrand disease (vWD). • Control of uremic bleeding after other treatment modalities have failed. Limitations of Use: Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used for replacement of factor VIII. CONTRAINDICATIONS Contraindicated for preparation of blood components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens. Contraindicated for preparation of blood components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen. WARNINGS AND PRECAUTIONS Only the INTERCEPT Blood System for Cryoprecipitation is approved for use to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex. For management of patients with vWD or factor XIII deficiency, Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used if recombinant or specific virally-inactivated factor preparations are available. In emergent situations, if recombinant or specific virally-inactivated factor preparations are not available, Pathogen Reduced Cryoprecipitated Fibrinogen Complex may be administered. ©2024 Cerus Corporation. Cerus, INTERCEPT, and the Cerus logo are registered trademarks of Cerus Corporation. MKT-EN 00685-55 v1.0

ICYMI, check out to Karina Anam, MD's presentation from #SCA2024! Dr. Anam shares The Ohio State University's experience with Pathogen Reduced Cryoprecipitated Fibrinogen Complex, commonly referred to as INTERCEPT® Fibrinogen Complex (#IFC), and how IFC improves patient access and minimizes wait times. IFC is an enriched source of fibrinogen, factor XIII, vWF, and other key clotting factors.  With a 5-day post-thaw shelf life, IFC can be pre-thawed and ready to transfuse immediately.* Webinar: https://bit.ly/4fx8RnT #IFC #INTERCEPT #Hemorrhage #cardiacsurgery #SCA2024 #massivehemorrhage #transfusionmedicine #hemostasis #bleedingcontrol #pathogenreduction #patientsafety See Package Insert (https://bit.ly/3Q1sfP7) for full prescribing information. * INTERCEPT Fibrinogen Complex is available for immediate use for up to 5 days when stored thawed; when stored frozen, requires thawing prior to use. INTERCEPT Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex: INDICATIONS FOR USE • Treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. • Control of bleeding when recombinant and/or specific virally inactivated preparations of factor XIII or von Willebrand factor (vWF) are not available. • Second-line therapy for von Willebrand disease (vWD). • Control of uremic bleeding after other treatment modalities have failed. Limitations of Use: Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used for replacement of factor VIII. CONTRAINDICATIONS Contraindicated for preparation of blood components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens. Contraindicated for preparation of blood components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen. WARNINGS AND PRECAUTIONS Only the INTERCEPT Blood System for Cryoprecipitation is approved for use to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex. For management of patients with vWD or factor XIII deficiency, Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used if recombinant or specific virally-inactivated factor preparations are available. In emergent situations, if recombinant or specific virally-inactivated factor preparations are not available, Pathogen Reduced Cryoprecipitated Fibrinogen Complex may be administered. MKT-EN 00685-61 v1.0

In a recent publication in the journal Blood Advances, Wheeler et al. report on additional findings from the largest platelets transfusion study assessing pulmonary injury to date. This new analysis assesses the impact of transfusion intensity with pathogen reduced platelets* compared to conventional platelets on pulmonary injury requiring assisted mechanical ventilation in hematology-oncology patients. This patient population frequently requires platelet transfusion due to antineoplastic therapy to address the underlying disease. Read the open access publication here: https://lnkd.in/g3Gp_ekj #platelets #transfusion #patientsafety *Platelets treated with the INTERCEPT Blood System have not been approved by FDA for reducing the probability of assisted mechanical ventilation during platelet transfusion. See package insert (https://ow.ly/yTLo50SStfe) for full prescribing information. CONTRAINDICATIONS Contraindicated for preparation of platelet components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens. Contraindicated for preparation of platelet components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth less than 375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen. WARNINGS AND PRECAUTIONS Only INTERCEPT Processing Sets for platelets are approved for use in the INTERCEPT Blood System. Use only the INTERCEPT INT100 Illuminator for UVA illumination of amotosalen-treated platelet components. No other source of UVA light may be used. Please refer to the Operator’s Manual for the INT100 Illuminator. Discard any platelet components not exposed to the complete INT100 illumination process. Tubing components and container ports of the INTERCEPT Blood System contain polyvinyl chloride (PVC). Di(2-ethylhexyl)phthalate (DEHP) is known to be released from PVC medical devices, and increased leaching can occur with extended storage or increased surface area contact. Blood components will be in contact with PVC for a brief period of time (approx. 15 minutes) during processing. The risks associated with DEHP released into the blood components must be weighed against the benefits of therapeutic transfusion. © 2024 Cerus Corporation. Cerus, INTERCEPT, and the Cerus logo are registered trademarks of Cerus Corporation. MKT-EN 00685-53 v1.0

As a result of the pandemic-driven shortages and concerns for bacterial and viral contamination associated with cryoprecipitated AHF for bleeding patients, Kaiser Permanente Los Angeles Medical Center implemented Pathogen Reduced Cryoprecipitated Fibrinogen Complex, commonly referred to as INTERCEPT® Fibrinogen Complex (#IFC). Earlier this month in the journal TRANSFUSION, Aidikoff et al. report their experience implementing IFC, describing its positive impact on blood bank operations, blood component utilization and length of stay. The abstract and publication can be found here: https://lnkd.in/g9X_XTqz #massivehemorrhage #transfusion #fibrinogen #cardiacsurgery #IFC #INTERCEPT INTERCEPT Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex: INDICATIONS FOR USE • Treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. • Control of bleeding when recombinant and/or specific virally inactivated preparations of factor XIII or von Willebrand factor (vWF) are not available. • Second-line therapy for von Willebrand disease (vWD). • Control of uremic bleeding after other treatment modalities have failed. Limitations of Use: Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used for replacement of factor VIII. CONTRAINDICATIONS Contraindicated for preparation of blood components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens. Contraindicated for preparation of blood components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen. WARNINGS AND PRECAUTIONS Only the INTERCEPT Blood System for Cryoprecipitation is approved for use to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex. For management of patients with vWD or factor XIII deficiency, Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used if recombinant or specific virally-inactivated factor preparations are available. In emergent situations, if recombinant or specific virally-inactivated factor preparations are not available, Pathogen Reduced Cryoprecipitated Fibrinogen Complex may be administered. MKT-EN 00685-57, v1.0

The CDC recently issued an advisory due to an increased risk of dengue virus infections in the US, with Puerto Rico declaring a public health emergency (1,498 cases) and US travelers experiencing a “higher-than-expected” number of cases (745) from 1/1 – 6/24/24.(1) Countries in the Americas have also encountered record-breaking dengue cases in the first half of 2024, with twice as many cases (9,386,082) reported than in all of 2023 (4,617,108).(2) The INTERCEPT® Blood System for Platelets Pathogen Reduction System inactivates certain emerging pathogens*, including dengue virus, to reduce TTI risk(3) and help sustain local platelet availability during outbreaks.(4) Learn more: https://ow.ly/6RFr50SwXeq *There is no pathogen inactivation process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19 and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process. 1.The Centers for Disease Control and Prevention. Increased Risk of Dengue VirusInfections in the United States. https://ow.ly/UHuw50SwXer 2.Pan American Health Organization. Epidemiological Update Increase in dengue casesin the Region of the Americas. https://ow.ly/ohpa50SwXes 3.The INTERCEPT Blood System for Platelets Package Insert, Cerus Corporation;December 19, 2023. 4.Allain, J.P., et al., Transfus Med Rev, 2005. 19(2): p. 110-26. CONTRAINDICATIONS Contraindicated for preparation of platelet components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens. Contraindicated for preparation of platelet components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth less than 375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen. WARNINGS AND PRECAUTIONS Only INTERCEPT Processing Sets for platelets are approved for use in the INTERCEPT Blood System. Use only the INTERCEPT INT100 Illuminator for UVA illumination of amotosalen-treated platelet components. No other source of UVA light may be used. Please refer to the Operator’s Manual for the INT100 Illuminator. Discard any platelet components not exposed to the complete INT100 illumination process. Tubing components and container ports of the INTERCEPT Blood System contain polyvinyl chloride (PVC). Di(2-ethylhexyl)phthalate (DEHP) is known to be released from PVC medical devices, and increased leaching can occur with extended storage or increased surface area contact. Blood components will be in contact with PVC for a brief period of time (approx. 15 minutes) during processing. The risks associated with DEHP released into the blood components must be weighed against the benefits of therapeutic transfusion. © 2024 Cerus Corporation. Cerus, INTERCEPT, and the Cerus logo are registered trademarks of Cerus Corporation. MKT-EN 00685-52 v1.0

When controlling hemorrhage, minutes matter! Hospitals across the U.S. are implementing Pathogen Reduced Cryoprecipitated Fibrinogen Complex, commonly referred to as INTERCEPT® Fibrinogen Complex (#IFC), as an enriched source of fibrinogen, factor XIII, vWF, and other key clotting factors, with a 5-day post-thaw shelf life, pre-thawed and ready to transfuse immediately.* Listen to Jonathan Meizoso, MD, MSPH, FACS, from The Ryder Trauma Center (Jackson Health System) and the University of Miami University of Miami Health System, discuss the importance of fibrinogen supplementation during hemorrhagic shock resuscitation, the University of Miami’s early experience with IFC and how IFC helps them achieve their treatment goals.   Webinar: https://bit.ly/3xqmwMi #IFC #INTERCEPT #pathogenreduction #bloodsafety #patientsafety #Hemorrhage #massivehemorrhage #transfusionmedicine #hemostasis #bleedingcontrol #EAST2024 INTERCEPT Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex: INDICATIONS FOR USE • Treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. • Control of bleeding when recombinant and/or specific virally inactivated preparations of factor XIII or von Willebrand factor (vWF) are not available. • Second-line therapy for von Willebrand disease (vWD). • Control of uremic bleeding after other treatment modalities have failed. Limitations of Use: Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used for replacement of factor VIII. CONTRAINDICATIONS Contraindicated for preparation of blood components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens. Contraindicated for preparation of blood components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen. WARNINGS AND PRECAUTIONS Only the INTERCEPT Blood System for Cryoprecipitation is approved for use to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex. For management of patients with vWD or factor XIII deficiency, Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used if recombinant or specific virally-inactivated factor preparations are available. In emergent situations, if recombinant or specific virally-inactivated factor preparations are not available, Pathogen Reduced Cryoprecipitated Fibrinogen Complex may be administered. MKT-EN 00685-51 v1.0

While fibrinogen is generally recognized as a critical blood clotting factor that can decline quickly in the massive hemorrhage patient, logistical challenges often prevent its rapid administration. Earlier this month, the American Journal of Clinical Pathology published the experience of Dr. Sethapati et al. with the implementation of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, commonly referred to as INTERCEPT Fibrinogen Complex (IFC), at Stanford Health Care’s Blood Bank. The publication, which details the positive impact of this blood component on waste and turnaround time at a single site, can be found here: https://ow.ly/HBIp50SAsrU #massivehemorrhage #transfusion #fibrinogen #IFC #INTERCEPT #AJCP INTERCEPT Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex: INDICATIONS FOR USE • Treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. • Control of bleeding when recombinant and/or specific virally inactivated preparations of factor XIII or von Willebrand factor (vWF) are not available. • Second-line therapy for von Willebrand disease (vWD). • Control of uremic bleeding after other treatment modalities have failed. Limitations of Use: Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used for replacement of factor VIII. CONTRAINDICATIONS Contraindicated for preparation of blood components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens. Contraindicated for preparation of blood components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen. WARNINGS AND PRECAUTIONS Only the INTERCEPT Blood System for Cryoprecipitation is approved for use to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex. For management of patients with vWD or factor XIII deficiency, Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used if recombinant or specific virally-inactivated factor preparations are available. In emergent situations, if recombinant or specific virally-inactivated factor preparations are not available, Pathogen Reduced Cryoprecipitated Fibrinogen Complex may be administered. MKT-EN 00685-56, v1.0

We recently met with Dr. Jerry E. Squires to discuss blood safety and the role of INTERCEPT treated platelets at the Medical University of South Carolina. “PR (pathogen-reduced) platelets provide a higher margin of safety through reduced bacterial contamination, viral and emerging infectious risk as well as reduced risk in inadvertently transfusing an unirradiated product. This is particularly important for our hematology-oncology patients who require large quantities of platelets and are exposed to many donors.” – Jerry E. Squires, M.D., PhD Medical Director of Transfusion Service Professor of Pathology and Transfusion Medicine Medical University of South Carolina Learn more about why hospitals like the Medical University of South Carolina use INTERCEPT treated platelets: hcp.intercept-usa.com #Cerus #INTERCEPT #pathogeninactivation #platelets #JOINTHEMOVEMENT CONTRAINDICATIONS Contraindicated for preparation of platelet components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens. Contraindicated for preparation of platelet components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth less than 375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen. WARNINGS AND PRECAUTIONS Only INTERCEPT Processing Sets for platelets are approved for use in the INTERCEPT Blood System. Use only the INTERCEPT INT100 Illuminator for UVA illumination of amotosalen-treated platelet components. No other source of UVA light may be used. Please refer to the Operator’s Manual for the INT100 Illuminator. Discard any platelet components not exposed to the complete INT100 illumination process. Tubing components and container ports of the INTERCEPT Blood System contain polyvinyl chloride (PVC). Di(2-ethylhexyl)phthalate (DEHP) is known to be released from PVC medical devices, and increased leaching can occur with extended storage or increased surface area contact. Blood components will be in contact with PVC for a brief period of time (approx. 15 minutes) during processing. The risks associated with DEHP released into the blood components must be weighed against the benefits of therapeutic transfusion. © 2024 Cerus Corporation. Cerus, INTERCEPT, and the Cerus logo are registered trademarks of Cerus Corporation. MKT-EN 00685-49 v1.0

Join over 80% of top cancer hospitals(1) using INTERCEPT® treated platelets (INTERCEPT Platelets). Leukemia and lymphoma patients are highly susceptible to bacterial and viral infection, with platelet transfusions posing a risk due to bacterial contamination.(2) INTERCEPT Platelets help protect patients by reducing bacterial contamination risk and inactivating viruses, protozoans, and leukocytes.* Help maximize success in patient treatment with reduced transfusion-transmitted infectious risk.(3) Read more: https://lnkd.in/gpmUzTjC #Cerus #INTERCEPT #pathogeninactivation #platelets #JOINTHEMOVEMENT *There is no pathogen inactivation process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19 and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process. 1. “Best Hospitals 2023-24”. U.S. News & World Report. https://lnkd.in/dx-htxk 2. Taplitz RA, et al. J Clin Oncol. 2018 Oct 20;36(30):3043-3054. 3. The INTERCEPT Blood System for Platelets Package Insert, Cerus Corporation; December 19, 2023. CONTRAINDICATIONS Contraindicated for preparation of platelet components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens. Contraindicated for preparation of platelet components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth less than 375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen. WARNINGS AND PRECAUTIONS Only INTERCEPT Processing Sets for platelets are approved for use in the INTERCEPT Blood System. Use only the INTERCEPT INT100 Illuminator for UVA illumination of amotosalen-treated platelet components. No other source of UVA light may be used. Please refer to the Operator’s Manual for the INT100 Illuminator. Discard any platelet components not exposed to the complete INT100 illumination process. Tubing components and container ports of the INTERCEPT Blood System contain polyvinyl chloride (PVC). Di(2-ethylhexyl)phthalate (DEHP) is known to be released from PVC medical devices, and increased leaching can occur with extended storage or increased surface area contact. Blood components will be in contact with PVC for a brief period of time (approx. 15 minutes) during processing. The risks associated with DEHP released into the blood components must be weighed against the benefits of therapeutic transfusion. ©2024 Cerus Corporation. Cerus, INTERCEPT, and the Cerus logo are registered trademarks of Cerus Corporation. MKT-EN 00685-50 v1.0